Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...
Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...
PHOENIX -- The investigational agent riliprubart, a complement C1s inhibitor, showed encouraging activity in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), according to a ...
(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody that ...
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ:DNTH), a recent reverse merger with the old Magenta Therapeutics. The analysts initiate with an Outperform rating and a price ...
SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...
The complement system has more than 50 soluble and membrane-bound proteins. In innate and adaptive immunity, complement is essential for eliminating foreign pathogens and apoptotic cells. It is also ...
Cold agglutinin disease (CAD) is a rare subtype of autoimmune haemolytic anaemia (AIHA) where autoantibodies, predominantly of the IgM class, bind to red blood cells at reduced temperatures. This ...
On Wednesday, Annexon Inc (NASDAQ:ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback